A novel cancer immunotherapy shows early promise in preclinical studies
Wednesday, January 11, 2017 - 11:21
in Health & Medicine
Scientists report that GARP, a TGF-beta cell surface receptor, could be a novel diagnostic marker for breast, colon, and lung cancer. An antibody-based therapy targeting GARP prevented metastasis to the lung in a mouse model of breast cancer. Targeting GARP with an antibody could represent a novel addition to established immunotherapies that 'wake up' the immune system so that it can fight cancer.